Addressing Unmet Needs in Chronic Phase CML With Third-Generation TKI

This publication is sponsored by Takeda Pharmaceuticals U.S.A., Inc.

This clinical brief provides key information on third-generation tyrosine kinase inhibitor for patients with chronic phase chronic myeloid leukemia (CP-CML). Interviews with Roy Beveridge, MD, and Paul B. Koller, MD, offer insights on the management of CP-CML from the payer and clinical perspectives.